Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2019

Open Access 01-12-2019 | Praziquantel | Research article

A prospective risk assessment of the implementation of a schistosomiasis preventive mass drug administration for children aged five years and below in the uMkhanyakude district of KwaZulu-Natal

Authors: Mhlengi Vella Ncube, Moses John Chimbari

Published in: BMC Health Services Research | Issue 1/2019

Login to get access

Abstract

Background

Schistosomiasis is endemic in the uMkhanyakude district of KwaZulu-Natal, South Africa. The South Africa Department of Health (DoH) has decided to implement a schistosomiasis preventive mass drug administration program in all affected parts of the country. Quality management is part of the strategic objectives of the treatment program. We conducted a risk assessment and developed guidelines for the quality management of a schistosomiasis preventive treatment program for children aged 5 years and below in the uMkhanyakude District of KwaZulu-Natal.

Methods

We conducted a scenario planning exercise by interviewing 10 child health experts from the uMkhanyakude Health District to establish potential risks associated with a planned schistosomiasis preventive control treatment program for children aged 5 years old and below. The risks were analyzed using a modified Failure Mode and Effect Analysis (FMEA). An FMEA table was produced to guide the quality management of the planned schistosomiasis preventive control treatment program for children aged 5 years and below in the uMkhanyakude Health District.

Results

We identified potential risks, failure modes and possible failure corrective/preventive measures in the following activities that would be part of the mass treatment of children aged 5 years and below infected with schistosomiasis in the uMkhanyakude District. These included enrolment of children into the treatment program; general health checks; weight and height measurements; administration of drugs; reporting of side effects and monitoring and evaluation.

Conclusion

We were able to use FMEA guide quality management and identify potential risks associated with the planned schistosomiasis preventive treatment program for children aged 5 years old and below in the uMkhanyakude District of KwaZulu-Natal. The FMEA for this program will be useful to the quality management of schistosomiasis preventive treatment programs for this age group in other similar settings.
Appendix
Available only for authorised users
Literature
1.
King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop. 2010;113(2):95–104.CrossRef
2.
3.
Chimbari M, Ndlela B. Successful control of schistosomiasis in large sugar irrigation estates of Zimbabwe. Cent Afr J Med. 2001;47(7):169–72.PubMed
4.
Wang W, Liang Y. Mass drug administration (MDA) for schistosomiasis. J Infect Dis. 2014;211(5):848–9.CrossRef
5.
Bronzan RN, et al. Impact of community-based integrated mass drug administration on schistosomiasis and soil-transmitted helminth prevalence in Togo. PLoS Negl Trop Dis. 2018;12(8):e0006551.CrossRef
6.
Chiozza ML, Ponzetti C. FMEA: a model for reducing medical errors. Clin Chim Acta. 2009;404(1):75–8.CrossRef
7.
Palha De Sousa CA, et al. Dosing of Praziquantel by Height in Sub-Saharan African Adults. Am J Trop Med Hyg. 2014;90(4):634–7.CrossRef
8.
Bateman C. Drug stock-outs: inept supply-chain management and corruption. S Afr Med J. 2013;103(9):600–2.CrossRef
9.
Tuhebwe D, et al. Uptake of mass drug administration Programme for schistosomiasis control in Koome Islands, Central Uganda. PLOS ONE. 2015;10(4):e0123673.CrossRef
10.
Lago P, et al. Use of FMEA analysis to reduce risk of errors in prescribing and administering drugs in paediatric wards: a quality improvement report. BMJ Open. 2012;2(6):e001249.CrossRef
11.
Mutapi F, et al. Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the antihelminthic drug praziquantel. PLoS Negl Trop Dis. 2011;5(5):e1143.CrossRef
12.
Navaratnam AMD, et al. Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety. Trans R Soc Trop Med Hyg. 2012;106(7):400–7.CrossRef
13.
Sousa-Figueiredo JC, Betson M, Stothard JR. Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole. Int Health. 2012;4(2):95–102.CrossRef
14.
Olliaro PL, et al. Practical dosing of praziquantel for schistosomiasis in preschool-aged children. Tropical Med Int Health. 2013;18(9):1085–9.CrossRef
15.
Sousa-Figueiredo J, et al. Performance and safety of Praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis. 2012;6(10):e1864.CrossRef
16.
Mduluza T, Mutapi F. Putting the treatment of paediatric schistosomiasis into context. Infect Dis Poverty. 2017;6:85.CrossRef
17.
Coulibaly JT, et al. Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis. 2012;6(12):e1917.CrossRef
18.
Coulibaly JT, et al. Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial. Lancet Glob Health. 2017;5(7):e688–98.CrossRef
19.
Coulibaly JT, et al. Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial. BMC Med. 2018;16(1):81.CrossRef
20.
Jeve YB. Raising quality whilst reducing cost in health care: a retrospective cohort study. Int J Health Plann Manag. 2018;33(1):e228–37.CrossRef
21.
Andel C, et al. The economics of health care quality and medical errors. J Health Care Finance. 2012;39(1):39.PubMed
22.
Lassetter JH, Warnick ML. Medical errors, drug-related problems, and medication errors: a literature review on quality of care and cost issues. J Nurs Care Qual. 2003;18(3):175–83.CrossRef
23.
Randjelovic A, et al. A study of hurdles in mass treatment of schistosomiasis in KwaZulu-Natal, South Africa. S Afr Fam Pract. 2015;57(2):57–61.
24.
Ndayishimiye O, et al. Control of neglected tropical diseases in Burundi: partnerships, achievements, challenges, and lessons learned after four years of Programme implementation. PLoS Negl Trop Dis. 2014;8(5):e2684.CrossRef
25.
Health Do. South Africa National Master Plan for the Elimination of Neglected Tropical Diseases (2019–2025). Johannesburg: South African Department of Health; 2019.
26.
Schriefer J, Leonard MS. Patient safety and quality improvement: an overview of QI. Pediatr Rev. 2012;33(8):353–9 quiz 359-60.CrossRef
27.
Liu H-C. FMEA for Proactive Healthcare Risk Analysis: A Systematic Literature Review. In: Improved FMEA Methods for Proactive Healthcare Risk Analysis. Singapore: Springer; 2019. p. 15–45.CrossRef
28.
Shaughnessy EE, et al. Quality improvement feature series article 1: introduction to quality improvement. J Pediatric Infect Dis Soc. 2017;7(1):6–10.CrossRef
29.
Ashley L, et al. A practical guide to failure mode and effects analysis in health care: making the Most of the team and its meetings. Jt Comm J Qual Patient Saf. 2010;36(8):351–8.CrossRef
30.
Ookalkar AD. Quality improvement in haemodialysis process using FMEA. Int J Qual &; Rel Manag. 2009;26(8):817–30.CrossRef
31.
32.
Kabuyaya M, et al. Efficacy of praziquantel on Schistosoma haematobium and re-infection rates among school-going children in the Ndumo area of uMkhanyakude district, KwaZulu-Natal, South Africa. Infect Dis Poverty. 2017;6(1):83.CrossRef
33.
Health Do. Province of KwaZulu-Natal Annual Report 2016/2017 Vote 7; 2017.
34.
Amer M, Daim TU, Jetter A. A review of scenario planning. Futures. 2013;46:23–40.CrossRef
35.
Coates JF. Scenario planning. Technol Forecast Soc Chang. 2000;65(1):115–23.CrossRef
36.
WHO. Schistosomiasis Progress Report (2001–2011) and Strategic Plan (2012–2020). Geneva: World Health Organization; 2013.
37.
Burnim M, Ivy JA, King CH. Systematic review of community-based, school-based, and combined delivery modes for reaching school-aged children in mass drug administration programs for schistosomiasis. PLoS Negl Trop Dis. 2017;11(10):e0006043.CrossRef
38.
Omedo M, et al. The effect of a health communication campaign on compliance with mass drug administration for schistosomiasis control in western Kenya—the SCORE project. Am J Trop Med Hyg. 2014;91(5):982–8.CrossRef
39.
Chami GF, et al. Community-directed mass drug administration is undermined by status seeking in friendship networks and inadequate trust in health advice networks. Soc Sci Med. 2017;183:37–47.CrossRef
40.
Gholami M, et al. Evaluation of the impact of a mass media campaign on periodontal knowledge among Iranian adults: a three-month follow-up. PLoS One. 2017;12(1):e0169668.CrossRef
41.
Muhumuza S, et al. Uptake of preventive treatment for intestinal schistosomiasis among school children in Jinja district, Uganda: a cross sectional study. PLoS One. 2013;8(5):e63438.CrossRef
42.
Chimbari MJ. Enhancing schistosomiasis control strategy for Zimbabwe: building on past experiences. J Parasitol Res. 2012;2012;1–9.CrossRef
43.
Sokhela D, Sibiya M, Gwele N. Monitoring well-baby visits in primary healthcare facilities in a middle-income country. S Afr J Child Health. 2018;12(2):44–7.CrossRef
44.
Were MC, et al. Evaluating a scalable model for implementing electronic health records in resource-limited settings. J Am Med Inform Assoc. 2010;17(3):237–44.CrossRef
45.
Millard PS, Bru J, Berger CA. Open-source point-of-care electronic medical records for use in resource-limited settings: systematic review and questionnaire surveys. BMJ Open. 2012;2(4):e000690.CrossRef
46.
Kabuyaya M, Chimbari MJ, Mukaratirwa S. Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review. Infectious diseases of poverty. 2018;7(1):73.CrossRef
47.
Corsi DJ, Mejía-Guevara I, Subramanian SV. Risk factors for chronic undernutrition among children in India: estimating relative importance, population attributable risk and fractions. Soc Sci Med. 2016;157:165–85.CrossRef
48.
Nalugwa A, et al. Single versus double dose Praziquantel comparison on efficacy and Schistosoma mansoni re-infection in preschool-age children in Uganda: a randomized controlled trial. PLoS Negl Trop Dis. 2015;9(5):e0003796.CrossRef
49.
Montresor A, Garba A. Treatment of preschool children for schistosomiasis. Lancet Glob Health. 2017;5(7):e640–1.CrossRef
50.
Osakunor DNM, Woolhouse MEJ, Mutapi F. Paediatric schistosomiasis: what we know and what we need to know. PLoS Negl Trop Dis. 2018;12(2):e0006144.CrossRef
51.
Magaisa K, et al. A review of the control of schistosomiasis in South Africa. S Afr J Sci. 2015;111:1–6.CrossRef
52.
53.
Blach O, et al. An outbreak of schistosomiasis in travellers returning from endemic areas: the importance of rigorous tracing in peer groups exposed to risk of infection. J Public Health. 2011;34(1):32–6.CrossRef
54.
Toor J, et al. The design of schistosomiasis monitoring and evaluation programmes: the importance of collecting adult data to inform treatment strategies for Schistosoma mansoni. PLoS Negl Trop Dis. 2018;12(10):e0006717.CrossRef
55.
Turner HC, et al. Economic considerations for moving beyond the Kato-Katz technique for diagnosing intestinal parasites as we move towards elimination. Trends Parasitol. 2017;33(6):435–43.CrossRef
56.
Michael E, Meyrowitsch D, Simonsen P. Cost and cost effectiveness of mass diethylcarbamazine chemotherapy for the control of bancroftian filariasis: comparison of four strategies in Tanzania. Tropical Med Int Health. 1996;1(4):414–26.CrossRef
57.
Flagg EW, et al. High prevalence and presumptive treatment of schistosomiasis and Strongyloidiasis among African refugees. Clin Infect Dis. 2007;45(10):1310–5.CrossRef
Metadata
Title
A prospective risk assessment of the implementation of a schistosomiasis preventive mass drug administration for children aged five years and below in the uMkhanyakude district of KwaZulu-Natal
Authors
Mhlengi Vella Ncube
Moses John Chimbari
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2019
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-019-4507-1

Other articles of this Issue 1/2019

BMC Health Services Research 1/2019 Go to the issue

Research article

Implementation of a billable transitional care model for stroke patients: the COMPASS study

Study protocol

Effectiveness of a psychoeducation group intervention conducted by primary healthcare nurses in patients with depression and physical comorbidity: study protocol for a randomized, controlled trial

Study protocol

Telephone-based aftercare groups for family carers of people with dementia: study protocol of the Talking Time – REHAB project

Research article

Patient and provider perspectives on how trust influences maternal vaccine acceptance among pregnant women in Kenya

Research article

Physician and pharmacist satisfaction and clinical needs for the real-time medication surveillance program in South Korea

Research article

Ethical challenges of seclusion in psychiatric inpatient wards: a qualitative study of the experiences of Norwegian mental health professionals